Cell­trion signs agree­ment for ath­er­o­scle­ro­sis drugs de­vel­op­ment

BioSpectrum (Asia) - - Company -

Cell­trion, a lead­ing bio­phar­ma­ceu­ti­cal com­pany head­quar­tered in In­cheon,

Korea has signed an In­cu­ba­tion agree­ment with Emory Univer­sity in At­lanta to sup­port the re­search and de­vel­op­ment of new drug can­di­dates for ath­er­o­scle­ro­sis. Un­der the agree­ment, Cell­trion will share its ac­cu­mu­lated bi­o­log­ics de­vel­op­ment ex­per­tise with Emory Univer­sity School of Medicine and the Wal­lace H. Coul­ter Depart­ment of Bio­med­i­cal En­gi­neer­ing at Emory Univer­sity and Ge­or­gia In­sti­tute of Tech­nol­ogy, and pro­vide re­search costs and man­u­fac­tur­ing ma­te­ri­als of new drug can­di­dates for ath­er­o­scle­ro­sis. Cell­trion will have a pref­er­en­tial right to ac­quire a li­cense for in­ven­tions re­sult­ing from the agree­ment.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.